Sara Radcliffe is the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously she served as BIO's Vice President for Science and Regulatory Affairs. Ms. Radcliffe has responsibility for identifying, developing and implementing strategic BIO approaches to improving the ability of BIO's human healthcare focused companies to research and develop products, and to bring these products to market. Before joining BIO, Ms. Radcliffe was Senior Director, Biologics & Biotechnology, and Assistant Vice-President, Preclinical Drug Safety Evaluation, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Among her responsibilities at PhRMA were to staff the PhRMA Vaccines CEOs Committee and the PhRMA Emergency Preparedness Task Force. She also worked for the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, where her work focused on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research, including Pharmacogenetics. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Ms. Radcliffe holds a Master's of Public Health and a Masters in Philosophy from the Johns Hopkins University.